<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857424</url>
  </required_header>
  <id_info>
    <org_study_id>21-000142</org_study_id>
    <nct_id>NCT04857424</nct_id>
  </id_info>
  <brief_title>Quality of Life Assessment Between Internal Endoscopic Versus Percutaneous Drainage in Biliary Obstruction</brief_title>
  <official_title>A Comparative Quality of Life Assessment Between Internal Endoscopic Versus Percutaneous Drainage of Benign and Malignant Biliary Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the quality of life in subjects with benign and malignant&#xD;
      biliary obstruction who have or will undergo endoscopic retrograde cholangiopancreatography&#xD;
      (ERCP) and/or percutaneous trans-hepatic biliary drainage (PTBD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in European Quality of Life-5 Dimensions questionnaire score</measure>
    <time_frame>Baseline, 1 month, 3 months</time_frame>
    <description>Measured using the European Quality of Life-5 Dimensions questionnaire that measures mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The Euro-QOL-5D score is derived from adding the scores from each of the five items. The best possible score is five (i.e., asymptomatic in each item) and the worst possible score is 15 (incapacitated in each item).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Biliary Obstruction</condition>
  <arm_group>
    <arm_group_label>ERCP</arm_group_label>
    <description>Subjects with benign and malignant biliary obstruction who have or will undergo endoscopic retrograde cholangiopancreatography (ERCP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTBD</arm_group_label>
    <description>Subjects with benign and malignant biliary obstruction who have or will undergo percutaneous trans-hepatic biliary drainage (PTBD).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients aged 18 or over with a diagnosis of benign or malignant biliary obstruction&#xD;
        who have underwent an ERCP and/or PTBD will be identified through Best Practices Advisory&#xD;
        (BPA), referrals from the clinics of GI consultants and the gastroenterology department&#xD;
        procedure schedules at Mayo Clinic, Rochester.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with benign biliary obstruction&#xD;
&#xD;
          -  Patients with malignant biliary obstruction&#xD;
&#xD;
          -  Patients undergoing ERCP and/or PTBD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with gallstone disease&#xD;
&#xD;
          -  Patients who will undergo ERCP who have previously underwent a PTBD&#xD;
&#xD;
          -  Patients who will undergo PTBD who have previously underwent an ERCP&#xD;
&#xD;
          -  Female patients who are pregnant&#xD;
&#xD;
          -  Prisoners and other vulnerable populations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Storm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William C Winter</last_name>
    <phone>507-422-5673</phone>
    <email>Winter.William@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tala Mahmoud, MD</last_name>
    <email>Mahmoud.Tala@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Andrew C. Storm</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

